p73 poses a barrier to malignant transformation by limiting anchorage-independent growth.
about
p73 as a pharmaceutical target for cancer therapyTP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy.Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation.Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathwayMonitoring the dynamics of clonal tumour evolution in vivo using secreted luciferasesMalignant transformation in a defined genetic background: proteome changes displayed by 2D-PAGETAp73 suppresses tumor angiogenesis through repression of proangiogenic cytokines and HIF-1α activity.p73 in Cancer.p53 Family: Role of Protein Isoforms in Human Cancer.Nuclear receptor CAR specifically activates the two-pore K+ channel Kcnk1 gene in male mouse livers, which attenuates phenobarbital-induced hepatic hyperplasia.Aneuploidy prediction and tumor classification with heterogeneous hidden conditional random fields.Metabolic pathways regulated by TAp73 in response to oxidative stressFunctions, divergence and clinical value of TAp73 isoforms in cancer.Piezo channels: from structure to function.A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression.The family of K2P channels: salient structural and functional properties.Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts.Tyr99 phosphorylation determines the regulatory milieu of tumor suppressor p73.Induction of the small heat shock protein alphaB-crystallin by genotoxic stress is mediated by p53 and p73.'Loss of pigment epithelium-derived factor enables migration, invasion and metastatic spread of human melanoma'.∆Np73 is capable of inducing apoptosis by co-ordinately activating several BH3-only proteins.MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
P2860
Q28611414-35273C96-E0A2-4AEE-8FE0-8E3252F796A5Q33358710-A1884C25-62DE-48A5-A2F3-D703787A36FAQ33375703-7B8D8270-5D29-44D7-8302-16F30D0CC823Q33737801-356D5DBB-39A8-4EF1-8A13-133D95A0A281Q33764406-D50FEC3E-156F-435B-BFA5-10191E0D8C34Q34202846-4C151B3B-99FC-497B-9310-4581A183FA21Q34926095-07A816CC-8D40-4954-A082-443B5C23B15AQ35103143-6003F95B-A6B9-4C29-91DC-753C8662674AQ35326348-F1CD380C-6105-432C-83D3-F7D118622F30Q36620491-DA817A35-2F79-4922-B5C4-19853F5404A5Q37181116-A0964528-9D37-459E-81D4-5093C2759704Q37327366-E494D9D5-EE47-492B-9955-8028F7178E93Q38099613-5ED404F5-6D7F-4EB3-8EB9-42CCE78E7CC9Q38231102-EDB7828D-0E66-4F0D-8E77-62195D5F1684Q38266299-3A3CE0B3-59CB-4DF7-AD34-C4D6BEA44EA8Q38296300-57EF5CBA-2788-49D3-8037-18977AB17587Q38558085-3A8EF4BF-B83A-4168-8461-27E44028A2E4Q38884723-5AEF520B-F9C0-4B06-88A4-5BEBB86DF6C3Q39795820-45496462-9E0F-4C53-8EB1-D4143F8C25E2Q39797139-BDF11DF8-59D9-4593-9326-56F2F65FA5A9Q40728552-0797E3F9-D771-4095-9DDC-F2206999361EQ52607219-673F1F14-251C-49EF-879B-C3CB62D6220D
P2860
p73 poses a barrier to malignant transformation by limiting anchorage-independent growth.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
p73 poses a barrier to malignant transformation by limiting anchorage-independent growth.
@en
type
label
p73 poses a barrier to malignant transformation by limiting anchorage-independent growth.
@en
prefLabel
p73 poses a barrier to malignant transformation by limiting anchorage-independent growth.
@en
P2093
P2860
P356
P1433
P1476
p73 poses a barrier to malignant transformation by limiting anchorage-independent growth.
@en
P2093
Andreas Rosenwald
Anne Catherine Bretz
Christof Burek
Claudia Oswald
Heidi Griesmann
Lars Hofmann
Michaela Beitzinger
Rasa Beinoraviciute-Kellner
P2860
P304
P356
10.1038/EMBOJ.2008.13
P407
P577
2008-01-31T00:00:00Z